Google
EXEL 株価分析 — Exelixis Inc (Healthcare >> Biotechnology)
EXEL に関するよくある質問
EXELのPER（株価収益率）は？
Exelixis Inc（EXEL）は現在PER 16.88倍で取引されています。
EXELのROE（自己資本利益率）は？
Exelixis IncのROEは43.05%です。
EXELの配当利回りは？
Exelixis Incの配当利回りは0.00%です。
EXELの品質スコア（Quality Score）は？
当社のAIはEXELの総合財務品質を100点中100点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
EXELは今が買い時ですか？
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
EXELはどのセクターに属しますか？
Exelixis IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
EXEL AI Analysis Summary
Our AI summary for EXEL: Exelixis Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 16.88, ROE of 43.05%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 53.03
Price
-2.94
(-5.25%)
Day Change
|
|
|---|
EXEL, ファンダメンタルスコアはexcellent ( ファンダメンタル = 100) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are ok , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
64% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.35 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
439
|
| Magic Formula Rank by ROE |
439
|
| Magic Formula Rank by ROIC |
473
|
| Price | 53.03 |
| PBV / Sector |
7.27 / 5.20
|
| Earning Per Share | 3.14 |
| PE / Sector |
16.88 / 19.97
|
| PEG or PE/Growth / Sector |
0.21 / 1.22
GREAT
|
| Average 1M Daily Value |
122.86 M
GREAT
|
| Average 1W Daily Value |
128.33 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
77% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:48 |
| Symbol | EXEL |
| Name | EXELIXIS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 251.36 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 14,068.34 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
Phone: 650 837 7000
Website: https://www.exelixis.com
Employees: 1,077
Sector: Healthcare >> Biotechnology
Description: Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
